Abstract
Integrated long-term efficacy and safety data on enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis type II (MPS II): Updated clinical data from Japan and Brazil
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have